CMPS241018C2500
- 3.20
- -0.30-8.57%
COMPASS Pathways Newsroom
MDMA Therapy For PTSD Faces FDA Delay: Are There Other Ways Forward?
RBC Capital Maintains COMPASS Pathways(CMPS.US) With Buy Rating, Maintains Target Price $23
Compass Pathways to Participate in Three Investor Conferences in September
Galapagos, XPeng, CorMedix And Other Big Stocks Moving Higher On Monday
Express News | HC Wainwright & Co. Reiterates Buy on Compass Pathways, Maintains $120 Price Target
Buy Rating Affirmed for COMPASS Pathways Amid Progress in Pivotal Trials and Strong Financial Position
CCORF Maintains COMPASS Pathways(CMPS.US) With Buy Rating, Maintains Target Price $48
Buy Rating Affirmed: COMPASS Pathways' Promising Clinical Trials Advance Psychedelic Therapeutics
Lykos Laying off 75% of Workforce Following FDA Rejection of Psychedelic Drug for PTSD
TD Cowen Maintains COMPASS Pathways(CMPS.US) With Buy Rating, Maintains Target Price $23
TD Cowen Remains a Buy on COMPASS Pathways (CMPS)
FDA Rejection of MDMA Therapy Isn't End of Psychedelic-Drug Candidates -- Barrons.com
Psychedelic Drug Contender Stocks Drop After FDA Rejects MDMA Treatment
Medical Journal Retracts Three Articles Related to MDMA for PTSD
Psychedelic Drug Developers Face Setback as Ecstasy-based Drug Rejected by FDA
COMPASS Pathways to Participate in Canaccord Genuity 44th Annual Growth Conference
Earnings Call: COMPASS Pathways Reports Q2 2024 Progress on Psilocybin Trials
COMPASS Pathways Plc (CMPS) Q2 2024 Earnings Call Transcript
Maxim Group Maintains COMPASS Pathways(CMPS.US) With Buy Rating, Maintains Target Price $22
COMPASS Pathways Poised for Growth With Strong Financials and Strategic Psychedelic Program Advancements